New trial finds arthritis drug tocilizumab no better than standard care for severe COVID-19
At 106, woman among earliest vaccine recipients in Brazil
20 January 2021Covid-19: Arthritis drug trial for severe illness is stopped early after increase in deaths
21 January 2021New trial finds arthritis drug tocilizumab no better than standard care for severe COVID-19
Adding the arthritis drug tocilizumab to standard care for patients in hospital with severe or critical COVID-19 is no better than standard care alone in improving clinical outcomes at 15 days, finds a new trial published by The BMJ today.
